Intrahepatic Cholangiocarcinoma
Conditions
Interventions
Experimental group:HAIC + Tislelizumab + Regorafenib
Sponsors
The Fifth Medical Center of Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years; 2.ECOG performance status <= 1; 3.Intrahepatic Cholangiocarcinoma; 4.Tumour lesions: Must be accurately measured in at least one dimension (RECIST 1.1); 5.Previous treatment with drug; 6.Good organ and bone marrow function.
Exclusion criteria
Exclusion criteria: 1.Allergic to PD-1/PD-L1 antibodies; 2.Patients who suffer from hypertension and cannot be reduced to the normal range after anti-hypertensive drug treatment; 3.Patients at risk of biliary obstruction; 4.Allergic to the drug of this protocol (Gemcitabine); 5.Patients with a clear tendency to gastrointestinal bleeding; 6.Patients who have immune system diseases and need to use Glucocorticoids and/or ICIs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Disease control rate;Overall survival;Improvement of quality of life; | — |
Countries
China
Contacts
Public ContactYinying Lu
The Fifth Medical Center of Chinese PLA General Hospital
Outcome results
None listed